Dutasteride vs Finasteride Results: The Hair Count Data (2026)

Introduction: The Question Every Hair Loss Searcher Is Really Asking

Men comparing dutasteride and finasteride are rarely looking for a pharmacology lecture. They are trying to decide which pill to start, and they want to know what their hairline, crown, and part will look like at 3, 6, and 12 months.

Most existing content fails them in one of two ways. Some pages rely on before-and-after photos that cannot be verified. Others bury readers in dense academic citations and SUCRA scores. Neither answers the practical question: what will a man actually see in the mirror?

This article takes the clinical outcome data (90 vs 57 hairs, 98% vs 71% DHT suppression, and network meta-analysis rankings) and turns it into a results timeline that readers can apply to their own scalp.

This decision matters to a very large number of men. Male pattern baldness reaches a prevalence of roughly 50% by age 50, and androgenetic alopecia affects about 30% of Caucasian men by age 30. This is a results-and-risk comparison, not a sales pitch. The goal is clarity before a prescription decision is made.

The Core Data: What the Head-to-Head Trials Actually Show

Before turning numbers into visible outcomes, the raw data needs to be laid out. Every figure below traces back to one biological difference. Dutasteride blocks both Type I and Type II 5-alpha reductase, the enzymes that convert testosterone into DHT. Finasteride blocks only Type II. That single distinction drives every gap that follows.

The 917-Man Trial: 90 Hairs vs 57 Hairs at 24 Weeks

The most frequently cited head-to-head study is a randomized trial of 917 men. At 24 weeks:

• Dutasteride 0.5 mg: mean increase of 90 hairs
• Finasteride 1 mg: mean increase of 57 hairs
• Placebo: decrease of nearly 5 hairs

The difference between dutasteride and finasteride was statistically significant (P = .003).

A Phase II trial reinforced the pattern. Over 24 weeks, dutasteride 0.5 mg increased target area hair count by approximately 109 hairs per cm², compared with roughly 75 for finasteride 1 mg and 33 for placebo.

In plain terms, dutasteride delivered roughly 58% more new hair growth than finasteride within the same 24-week window, with several studies finding it induces hair regrowth more rapidly and to a greater extent than even the highest approved dosage of finasteride.

DHT Suppression: 98% vs 71%, and Why the Gap Matters

A study of 399 subjects measured how thoroughly each drug lowered DHT:

Even at a tenfold lower dose, dutasteride blocked DHT considerably more effectively than finasteride.

The variability figures matter as much as the averages. Dutasteride’s ±1.2% spread is far tighter than finasteride’s ±18.3%. That means more predictable results from one man to the next, not just a higher average. The reason is straightforward: blocking both DHT-producing enzymes leaves fewer pathways for DHT to be made, so suppression is both deeper and steadier.

The Meta-Analyses Verdict: SUCRA Rankings Explained Simply

SUCRA (Surface Under the Cumulative Ranking Curve) is a probability score that estimates which treatment is most likely to be the best. It is not a percentage of hair gained. A higher SUCRA simply means a treatment ranked near the top more consistently.

Three independent analyses point in the same direction:

• 2022 JAMA Dermatology network meta-analysis (23 studies): Oral dutasteride 0.5 mg ranked most efficacious, followed by finasteride 5 mg, oral minoxidil, finasteride 1 mg, and topical minoxidil. Dutasteride outperformed finasteride 1 mg by a mean difference of 7.1 hairs/cm², consistent with low-dose dutasteride topping rankings of the most commonly used oral and topical agents.
• 2024 expanded analysis (33 studies): Dutasteride 0.5 mg ranked highest for 6-month total hair density (SUCRA 87%) and terminal hair density (SUCRA 98%).
• 2025/2026 network meta-analysis: Dutasteride 0.5 mg produced a 19 hairs/cm² mean improvement over control, with SUCRA scores of 95.8% in the base analysis and 94% when adjusted for severity.

Across analyses spanning 2022 to 2026, dutasteride 0.5 mg is the most consistent top performer.

Translating Hair Counts Into What Readers Will See in the Mirror

A “hairs per cm²” figure means little until it is mapped to a visible timeline. The averages below are the best predictive benchmark available, but individual results vary by Norwood stage, genetics, and consistency of use.

Month 3: Shedding Slows, Early Signs

By month 3, DHT suppression is near its peak, but visible hair count change is still minimal. This is the stabilization phase, not the regrowth phase. Follicles that were shrinking begin to recover, yet new growth has not had time to become visible.

Some users report subtle early changes around this point. Thryve Hair Lab testimonials describe a hairline “filling in” and baby hairs returning at the front at about 3 months. These accounts are anecdotal and not trial-verified at this exact interval. Patience is required, because both drugs show their largest separation later in the treatment window.

Month 6: The 90 vs 57 Hair Gap Becomes Visible

The 24-week mark is where the core trial data was measured. At this point, dutasteride users are statistically more likely than finasteride users to notice visible thickening at the crown or along the part line.

A difference of roughly 33 hairs in the 917-man trial (or about 34 hairs/cm² in the separate Phase II trial) is not a dramatic transformation. In practice, it looks like a noticeably denser part line and less scalp showing through in photos and under overhead lighting.

A 2025 randomized trial published in JAAD International supports this pattern. Thrice-weekly dutasteride produced a terminal hair gain of 17.43 hairs/cm² compared with 12.81 hairs/cm² for daily finasteride, and it was more likely to produce significant hair restoration (35% vs 21% of subjects). Even with less frequent dosing, dutasteride tended to outperform daily finasteride by month 6.

Month 12: Peak Results and Long-Term Density

Between months 9 and 12, most trial and real-world data show peak visible improvement in thickness and coverage. Given dutasteride’s higher and more consistent DHT suppression, the gap seen at 6 months tends to persist or widen slightly by 12 months, though individual response still varies.

This is maintenance therapy, not a cure. Both drugs require continued daily (or near-daily) use to keep the gains measured at this stage.

Why DHT Suppression Percentage Doesn’t Equal Proportional Hair Gains

A 27-percentage-point gap in DHT suppression does not produce a hair count gain that is 27% bigger. Biology has diminishing returns. Once DHT falls below a certain threshold, follicle miniaturization slows dramatically, so the benefit curve flattens even as suppression climbs toward 98%.

The real-world takeaway is balanced. The roughly 58% hair count advantage (90 vs 57) remains meaningful and clinically significant. Readers simply should not expect results to scale in a straight line with the suppression percentage.

Dual-Enzyme Blocking vs Single-Enzyme: The Mechanism Behind the Numbers

• Type I 5-alpha reductase is concentrated in the skin and scalp, including sebaceous glands.
• Type II 5-alpha reductase is concentrated in hair follicles and prostate tissue.

Finasteride addresses only Type II. Dutasteride addresses both, which shuts down a broader share of scalp DHT production. That broader coverage is the root cause of the hair count gap in every trial cited above.

Half-Life and Consistency: Why Dutasteride’s Suppression Is More Reliable

Dutasteride has a terminal half-life of about 5 weeks. Finasteride’s is about 5 to 6 hours. Finasteride levels rise and fall within each day, while dutasteride keeps DHT suppression steady between doses.

That stability likely explains the ±1.2% vs ±18.3% variability difference and the more predictable results across populations. The flip side is that dutasteride stays in the bloodstream for 4 to 6 months after the last dose, compared with about 1 month for finasteride.

Safety and Side Effects: What the Data Says Beyond Hair Counts

Larger hair count gains mean little without an equally clear look at risk. One regulatory distinction should be noted upfront: finasteride has been FDA-approved for hair loss since 1997, while dutasteride is prescribed off-label for this purpose in the U.S. This affects prescribing norms, not necessarily safety outcomes.

Sexual Side Effects: Statistical Parity Between the Two Drugs

A meta-analysis of 3 randomized trials involving 576 men found that dutasteride outperformed finasteride on hair counts and photo ratings, with no significant difference between the two drugs in loss of libido, erectile dysfunction, or ejaculation problems.

At the population level, sexual dysfunction occurs in roughly 3.4% to 15.8% of men taking either drug. The more effective option does not carry a meaningfully higher sexual side-effect risk.

For comparison, Thryve Hair Lab reports that fewer than 0.3% of its users experience mild, temporary sexual side effects. This figure is company-reported rather than independently peer-reviewed, but it offers a real-world reference point alongside trial ranges.

The 2025 FDA/EMA Mental Health Warnings to Know

Mental health concerns have built over time:

• 2011: FDA recognized depression as a possible finasteride side effect.
• 2022: FDA added suicidal thoughts to the finasteride label.
• May 2025: The European Medicines Agency’s safety committee confirmed suicidal thoughts as a side effect of finasteride.

A 2025 analysis of the FDA Adverse Event Reporting System (FAERS) also evaluated suicidality risk signals tied specifically to finasteride, finding that finasteride has been associated with depression and suicide for more than twenty years. Few comparison pages present this information alongside efficacy data. It is included here as context, not alarm, and it is especially relevant to side-effect-sensitive men.

For readers considering topical options, the FDA also issued an April 2025 safety alert on adverse events linked to compounded topical finasteride products.

Washout Period and Practical Considerations

Half-life has concrete consequences. The FDA defers blood donation for 6 months after the last dutasteride dose, compared with 1 month after stopping finasteride. Because dutasteride remains detectable for 4 to 6 months, men planning to switch medications, pause treatment, donate blood, or prepare for a procedure should plan around this window with their provider.

Emerging Data: Topical Dutasteride and Alternative Dosing

Much of the comparison content written before 2025 has not caught up to the newest trials. This section is informational. Thryve’s formula uses oral dutasteride.

2025 Phase II Topical Dutasteride Results

A 2025 Phase II randomized controlled trial found that topical dutasteride 0.05% w/v significantly outperformed oral finasteride 1 mg in target area hair count at 24 weeks (p = 0.0083), with no adverse events or irritation reported.

Satisfaction with hair on top of the head at week 24:

• Topical dutasteride: 96.55%
• Oral finasteride: 71.43%
• Placebo: 33.33%

Topical delivery may eventually pair dutasteride’s efficacy with a different side-effect profile. It is worth watching, but it is not yet as established as oral dosing.

Twice vs Thrice Weekly Dosing Study Findings

The 2025 JAAD International dosing trial showed:

• Twice-weekly dutasteride: 7.74 hairs/cm²
• Thrice-weekly dutasteride: 17.43 hairs/cm²
• Once-daily finasteride: 12.81 hairs/cm²

Even dutasteride taken three times weekly outperformed daily finasteride, which may matter for men concerned about long-term systemic exposure. Daily oral dutasteride, as used in Thryve’s formula, sits at or above the dosing frequency shown to outperform finasteride.

Dutasteride vs Finasteride: The Scenario-Based Verdict

With the data and timeline established, the practical question becomes which drug fits a given situation. This is general education based on clinical data, not a substitute for guidance from a licensed provider.

For Finasteride Non-Responders or Plateaued Users

When finasteride results stall, the data (90 vs 57 hairs, plus deeper and steadier DHT suppression) suggests dutasteride’s dual-enzyme action may reach DHT sources finasteride leaves untouched. No widely cited RCT measures the additional gain from switching after a plateau, so this is a mechanism-based rationale rather than a guaranteed numeric improvement. Any transition should be provider-guided, keeping dutasteride’s long washout in mind.

For Side-Effect-Sensitive Users

The 576-man meta-analysis showed no significant difference in sexual side effects, so moving to the more effective drug does not statistically raise that risk. The 2025 FDA and EMA mental health findings, however, are something this group should discuss directly with a licensed provider before starting either medication. For these men, individualized screening, such as Thryve’s doctor-guided questionnaire and provider review, matters as much as drug choice.

For First-Time Starters

First-time users have no non-responder history pulling them toward finasteride by default. Given dutasteride’s consistent lead across three independent meta-analyses and the original head-to-head RCT, starting with the statistically stronger option is a reasonable approach.

Early action also matters. A real-world UK study of 502 men found that 92.4% achieved stable or improved outcomes over 12 months on combined oral minoxidil and finasteride. Starting effective treatment early, using it consistently, and pairing it with complementary ingredients like minoxidil tends to outperform waiting. First-time starters benefit most from reviewing both the efficacy data and the 2025 safety context before committing to a year-long regimen.

What Happens If You Stop: Relapse and Long-Term Planning

Hair loss resumes approximately 6 to 12 months after stopping either finasteride or dutasteride. Neither drug produces a permanent, treatment-free result.

This is a planning consideration, not a deterrent. The gains documented throughout this article depend on consistent, ongoing use. That is why adherence-friendly delivery, with a steady monthly supply and no missed refills, matters as much as which drug is chosen.

How Thryve’s 4-in-1 Formula Fits Into These Results

Thryve Hair Lab’s once-daily capsule contains 0.5 mg dutasteride, the exact dose used across nearly every trial and meta-analysis cited above, combined with:

• Minoxidil 2.5 mg to stimulate follicles through improved blood flow
• Biotin 1 mg to support keratin production
• Vitamin D3 600 IU to support follicle health

Dutasteride and minoxidil work through different pathways. Dutasteride reduces the DHT that shrinks follicles, while minoxidil stimulates growth. Combining them addresses both causes of thinning in a single regimen.

The process is built for consistency and privacy: a doctor-guided online questionnaire, licensed provider review, 2-day FedEx shipping, discreet packaging, and a 1-year satisfaction guarantee. Thryve reports that 97 to 98% of men stop further loss and 90% see visible improvement within 3 to 6 months. These are company-level figures, and they align directionally with the third-party trial data.

Conclusion: Turning the Data Into a Decision

Across the 917-man RCT, three independent network meta-analyses, and a 2025 dosing-frequency trial, dutasteride 0.5 mg consistently shows a measurable advantage over finasteride in hair count and DHT suppression, without a statistically meaningful increase in sexual side effects.

Visible change is realistic by month 6, with peak results around months 9 to 12, and both drugs require continued use to maintain gains. The 2025 FDA and EMA mental health findings warrant a conversation with a licensed provider regardless of which drug is chosen.

The original question (which drug, what results, by when) can now be answered with data rather than guesswork.

Start a Personalized Hair Loss Assessment with Thryve

The next step is simple. Thryve Hair Lab’s 2 to 3 minute online questionnaire connects men with a licensed provider who evaluates Norwood stage, history, and individual risk factors.

• No office visit required
• Provider review within about 1 business day
• Full refund if treatment is not approved
• 1-year satisfaction guarantee on the treatment

Follicles respond best when treatment begins early, and every month of continued DHT exposure is a month of lost density. Rather than researching indefinitely, men ready to act can start their Thryve assessment today and get a clear, doctor-guided plan for protecting and rebuilding their hair.